bcl-2

(redirected from Bcl-2 protein)
Also found in: Medical, Wikipedia.

bcl-2

(biochemistry)
A family of proteins that operate in the effector phase of apoptosis and may either promote or inhibit apoptosis.
References in periodicals archive ?
The BCL-2 protein prevents apoptosis of some cells, including lymphocytes, and can be overexpressed in some cancer types.
The Bcl-2 protein family is an important regulator in apoptotic process, and includes the anti-apoptotic proteins [Bcl.
The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis.
One of the best-understood Bcl-2 proteins is called BAX, which promotes apoptosis by competing with another Bcl-2 protein (called Bcl-2 proper) that inhibits apoptosis (Lane 2006; Wong and Puthalakath 2008).
EBV produces two bcl-2 protein homologues, BHRF1 (20) and BALF1 (21).
We performed an immunohistochemical analysis of the expression of proliferating cell nuclear antigen (PCNA) and bcl-2 protein in 15 patients with laryngeal BSCC and 15 stage- and site- matched controls with typical laryngeal SCC.
Mutation of tyrosine to serine at the 21st amino acid of the Bcl-2 protein BH4 domain resulted in a loss both of suppression of JNK1/2 phosphorylation and its anti-apoptotic function.
Progesterone receptor modulator CDB-2914 down regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphateribose) polymerase expression in cultured human uterine leiomyoma cells," Journal of Clinical Endocrinology& Metabolism 90(2): 953-961.
WASHINGTON -- Elevated levels of the Bcl-2 protein in urine were associated with 92% of ovarian cancers in a pilot study of 95 women, Patricia Kruk, Ph.
G3139 is a mixture of synthesized DNA pieces "that basically glue themselves to RNA and prevent the Bcl-2 protein from being produced," says clinical pharmacologist Burkhard Jansen of the University of Vienna, who reported the findings.
These allowed claims will offer broad protection for the use of an antisense approach to controlling the gene expression of the BCL-2 protein.